(SLQT) Selectquote - Overview
Stock: Medicare, Life, Auto, Home, Pharmacy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 101% |
| Relative Tail Risk | -14.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.13 |
| Alpha | -94.44 |
| Character TTM | |
|---|---|
| Beta | 1.281 |
| Beta Downside | 1.520 |
| Drawdowns 3y | |
|---|---|
| Max DD | 82.98% |
| CAGR/Max DD | -0.21 |
Description: SLQT Selectquote December 28, 2025
SelectQuote, Inc. (NYSE: SLQT) runs a technology-driven, direct-to-consumer platform that markets and sells a range of insurance and health-care products in the United States. The business is organized into three segments-Senior (Medicare Advantage, Medicare Supplement, Part D, and related ancillary products plus lead-generation services), Healthcare Services (the SelectRx pharmacy network, Healthcare Select risk-assessment tools, Home™ pharmacy, and the SelectPatient Management chronic-condition platform), and Life (term life, final-expense and other ancillary policies). It also offers non-commercial auto, home, property and casualty coverage.
According to the company’s 2023 Form 10-K, SelectQuote generated roughly $1.1 billion in revenue, a modest year-over-year increase driven primarily by growth in its Senior segment, which benefited from a 4 % rise in Medicare-eligible enrollment (the U.S. 65-plus population is projected to reach 78 million by 2030). The firm’s operating margin remained thin, hovering around 2 %, reflecting ongoing investment in digital acquisition channels and the high cost of lead generation. A key sector driver is the broader P&C underwriting cycle; softening loss ratios in property-casualty lines have begun to improve profitability for insurers that can leverage data-rich platforms like SelectQuote’s Home™ (PCPH) offering.
Analysts also watch the company’s customer-acquisition cost (CAC) and lifetime value (LTV) metrics, which have trended lower as the platform scales-SelectQuote reported a 12 % decline in CAC YoY, while LTV grew by about 8 % in 2023, suggesting improving economics for its direct-to-consumer model.
For a deeper dive into how SLQT’s valuation stacks up against peers, you might explore the analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 61.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -3.18 > 1.0 |
| NWC/Revenue: 7.44% < 20% (prev 10.15%; Δ -2.71% < -1%) |
| CFO/TA -0.01 > 3% & CFO -16.7m > Net Income 61.7m |
| Net Debt (412.1m) to EBITDA (133.2m): 3.09 < 3 |
| Current Ratio: 1.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (185.8m) vs 12m ago 9.03% < -2% |
| Gross Margin: 35.89% > 18% (prev 0.45%; Δ 3544 % > 0.5%) |
| Asset Turnover: 132.8% > 50% (prev 120.4%; Δ 12.37% > 0%) |
| Interest Coverage Ratio: 1.67 > 6 (EBITDA TTM 133.2m / Interest Expense TTM 68.2m) |
Altman Z'' 0.20
| A: 0.10 (Total Current Assets 332.0m - Total Current Liabilities 215.7m) / Total Assets 1.21b |
| B: -0.21 (Retained Earnings -252.6m / Total Assets 1.21b) |
| C: 0.10 (EBIT TTM 114.0m / Avg Total Assets 1.18b) |
| D: -0.38 (Book Value of Equity -250.9m / Total Liabilities 660.0m) |
| Altman-Z'' Score: 0.20 = B |
Beneish M -2.68
| DSRI: 0.95 (Receivables 297.9m/276.3m, Revenue 1.56b/1.38b) |
| GMI: 1.25 (GM 35.89% / 44.80%) |
| AQI: 1.00 (AQ_t 0.69 / AQ_t-1 0.70) |
| SGI: 1.13 (Revenue 1.56b / 1.38b) |
| TATA: 0.06 (NI 61.7m - CFO -16.7m) / TA 1.21b) |
| Beneish M-Score: -2.68 (Cap -4..+1) = A |
What is the price of SLQT shares?
Over the past week, the price has changed by -22.54%, over one month by -21.99%, over three months by -34.52% and over the past year by -75.56%.
Is SLQT a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SLQT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.5 | 309.1% |
| Analysts Target Price | 4.5 | 309.1% |
| ValueRay Target Price | 0.9 | -19.1% |
SLQT Fundamental Data Overview February 03, 2026
P/E Forward = 66.6667
P/S = 0.1599
P/B = 0.8306
Revenue TTM = 1.56b USD
EBIT TTM = 114.0m USD
EBITDA TTM = 133.2m USD
Long Term Debt = 324.8m USD (from longTermDebt, last quarter)
Short Term Debt = 73.2m USD (from shortTermDebt, last quarter)
Debt = 422.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 412.1m USD (from netDebt column, last quarter)
Enterprise Value = 662.0m USD (249.9m + Debt 422.8m - CCE 10.7m)
Interest Coverage Ratio = 1.67 (Ebit TTM 114.0m / Interest Expense TTM 68.2m)
EV/FCF = -27.15x (Enterprise Value 662.0m / FCF TTM -24.4m)
FCF Yield = -3.68% (FCF TTM -24.4m / Enterprise Value 662.0m)
FCF Margin = -1.56% (FCF TTM -24.4m / Revenue TTM 1.56b)
Net Margin = 3.95% (Net Income TTM 61.7m / Revenue TTM 1.56b)
Gross Margin = 35.89% ((Revenue TTM 1.56b - Cost of Revenue TTM 1.00b) / Revenue TTM)
Gross Margin QoQ = 20.36% (prev 30.12%)
Tobins Q-Ratio = 0.55 (Enterprise Value 662.0m / Total Assets 1.21b)
Interest Expense / Debt = 2.79% (Interest Expense 11.8m / Debt 422.8m)
Taxrate = 1.92% (931.0k / 48.5m)
NOPAT = 111.8m (EBIT 114.0m * (1 - 1.92%))
Current Ratio = 1.54 (Total Current Assets 332.0m / Total Current Liabilities 215.7m)
Debt / Equity = 0.77 (Debt 422.8m / totalStockholderEquity, last quarter 546.9m)
Debt / EBITDA = 3.09 (Net Debt 412.1m / EBITDA 133.2m)
Debt / FCF = -16.90 (negative FCF - burning cash) (Net Debt 412.1m / FCF TTM -24.4m)
Total Stockholder Equity = 501.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.24% (Net Income 61.7m / Total Assets 1.21b)
RoE = 12.29% (Net Income TTM 61.7m / Total Stockholder Equity 501.6m)
RoCE = 13.80% (EBIT 114.0m / Capital Employed (Equity 501.6m + L.T.Debt 324.8m))
RoIC = 13.92% (NOPAT 111.8m / Invested Capital 803.5m)
WACC = 5.67% (E(249.9m)/V(672.7m) * Re(10.64%) + D(422.8m)/V(672.7m) * Rd(2.79%) * (1-Tc(0.02)))
Discount Rate = 10.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.63%
Fair Price DCF = unknown (Cash Flow -24.4m)
EPS Correlation: 20.16 | EPS CAGR: 3.23% | SUE: -2.86 | # QB: 0
Revenue Correlation: 69.31 | Revenue CAGR: 15.07% | SUE: 0.35 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=-0.010 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-06-30): EPS=0.11 | Chg30d=+0.010 | Revisions Net=-1 | Growth EPS=-55.3% | Growth Revenue=+10.8%
EPS next Year (2027-06-30): EPS=0.44 | Chg30d=+0.300 | Revisions Net=-1 | Growth EPS=+300.0% | Growth Revenue=+8.0%